Michael A Coleman

US Patent:

8088340, Jan 3, 2012

Filed:

Mar 14, 2006

Appl. No.:

11/908170

Inventors:

Mitsutaka Matsumoto - Tokyo, JP
Sumio Shibahara - Tokyo, JP
Takayuki Matsumoto - Tokyo, JP
Kanehisa Yokoyama - Tokyo, JP
Sohei Funaoka - Tokyo, JP
Daisuke Masuda - Tokyo, JP
Michael Patrick Coleman - Louisville CO, US
Dominic Zichi - Boulder CO, US

Assignee:

Sumitomo Bakelite Company, Ltd. - Tokyo
Somalogic, Inc. - Boulder CO

International Classification:

G01N 33/52

US Classification:

422420, 422425, 525 541, 4352872, 4352877, 4352878

Abstract:

A biochip substrate capable of realizing the high detection accuracy by restricting a nonspecific adsorption or bonding of a substance to be detected, when used for a detection or analysis of protein, nucleic acids and the like. The biochip substrate is for fixing a biologically active substance on a surface of a solid substrate, and characterized in that it has a layer comprising a polymer compound obtained by copolymerizing an ethylenically unsaturated polymerizable monomer having an alkylene glycol residue, an ethylenically unsaturated polymerizable monomer having a functional group for fixing a biologically active substance and an ethylenically unsaturated polymerizable monomer having a cross-linkable functional group, on the surface of the substrate.

US Patent:

8293190, Oct 23, 2012

Filed:

Nov 29, 2011

Appl. No.:

13/306240

Inventors:

Mitsutaka Matsumoto - Tokyo, JP
Sumio Shibahara - Tokyo, JP
Takayuki Matsumoto - Tokyo, JP
Kanehisa Yokoyama - Tokyo, JP
Sohei Funaoka - Tokyo, JP
Daisuke Masuda - Tokyo, JP
Michael Patrick Coleman - Louisville CO, US
Dominic Zichi - Boulder CO, US

Assignee:

Sumitomo Bakelite Company, Ltd. - Tokyo
Somalogic, Inc. - Boulder CO

International Classification:

G01N 33/52

US Classification:

422420, 422425, 525 541, 4352872, 4352877, 4352878

Abstract:

A biochip substrate capable of realizing the high detection accuracy by restricting a nonspecific adsorption or bonding of a substance to be detected, when used for a detection or analysis of protein, nucleic acids and the like. The biochip substrate is for fixing a biologically active substance on a surface of a solid substrate, and characterized in that it has a layer comprising a polymer compound obtained by copolymerizing an ethylenically unsaturated polymerizable monomer having an alkylene glycol residue, an ethylenically unsaturated polymerizable monomer having a functional group for fixing a biologically active substance and an ethylenically unsaturated polymerizable monomer having a cross-linkable functional group, on the surface of the substrate.

US Patent:

20070275911, Nov 29, 2007

Filed:

Sep 7, 2004

Appl. No.:

10/570471

Inventors:

Tad Koch - Boulder CO, US
Michael Coleman - Louisville CO, US
Peter Cogan - Boulder CO, US
Patrick Burke - Seattle WA, US
Glen Post - Spokane WA, US
David Burkhart - Spokane WA, US
Andrew McKenzie - Belmont MA, US
Katrina Jackson - Boulder CO, US
Brian Kalet - Boulder CO, US

International Classification:

A61K 38/14
A61K 31/497
C07D 401/02
C07H 15/252
A61K 31/704

US Classification:

514034000, 514187000, 514253060, 514312000, 514053000, 536055000, 536006400, 544363000, 546010000, 546156000, 514008000

Abstract:

The invention provides a prodrug platform technology for improving the therapeutic value of a variety of parent drug compounds by altering and improving drug characteristics such as aqueous solubility, hydrolytic stability, therapeutic index, toxicity profile, pharmacolcinetics and selectivity while allowing the potential for synthetic elaboration. The prodrug platform is particularly well suited for targeting therapeutic drugs, including anti-tumor drugs and antibiotics, to specific receptors on target cells (e.g., cancer cells and bacteria). The platform is a technology for providing an improved, preactivated form of a therapeutic drug, and for optionally targeting such drug to target cells or biological molecules. The invention is broadly applicable to many different therapeutic drugs, as well as to a variety of diseases and conditions, including a variety of forms of cancer and bacterial infections.

US Patent:

20170015725, Jan 19, 2017

Filed:

Mar 11, 2015

Appl. No.:

15/124080

Inventors:

Allison D. Ortigosa - Harrisonburg VA, US
Michael P. Coleman - Louisville CO, US
Shibu T. George - Thornton CO, US
Michael A. Rauscher - Garwood NJ, US
Mark C. Sleevi - Longmont CO, US
Kartoa Chow - San Francisco CA, US
- Rahway NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

C07K 14/62
C07K 1/20
C07K 1/18

Abstract:

A process is described for purifying insulin and insulin analogs that comprises high-pressure liquid chromatography with an acidic cation exchange medium performed in the presence of a water miscible organic modifier and at an elevated temperature followed by reverse phase chromatography performed in the presence of a water miscible organic modifier and at an elevated temperature.